Hikma Pharmaceuticals Plc Hikma enters agreement to commercialise Ryaltris(TM)

Data : 27/02/2020 @ 08:05
Fonte : RNS Non-Regulatory
Titolo : Hikma Pharmaceuticals Plc (HIK)
Quotazione : 2330.0  -62.0 (-2.59%) @ 17:35
Quotazione Hikma Pharmaceuticals Grafico

Hikma Pharmaceuticals Plc Hikma enters agreement to commercialise Ryaltris(TM)

TIDMHIK

Hikma Pharmaceuticals Plc

27 February 2020

London, February 27, 2020 - Hikma Pharmaceuticals PLC (Hikma, Group), the multinational generic pharmaceutical company, and Glenmark Specialty S.A., a Swiss subsidiary of Glenmark Pharmaceuticals, a global innovative pharmaceutical company, today announce the signing of an exclusive US license agreement to commercialise Ryaltris(TM) (olopatadine hydrochloride and mometasone furoate nasal spray), an investigational fixed-dose combination nasal spray for the treatment of seasonal allergic rhinitis (SAR).

Under the terms of the agreement, Glenmark will be responsible for the continued development and regulatory approval of Ryaltris(TM) by the US Food and Drug Administration (FDA). Hikma will be responsible for the commercialisation of Ryaltris(TM) in the US following approval. Hikma would also have the ability to produce the product utilizing its nasal manufacturing capabilities in Columbus, Ohio. Hikma will provide Glenmark with an upfront payment, regulatory approval and commercial milestone payments as well as royalties.

"We are pleased to form this partnership with Glenmark, which builds on our market-leading position in nasal allergy sprays and advances our objective of growing our specialty business in the US," said Brian Hoffmann, President of Hikma Generics. "Hikma is the largest supplier of generic nasal sprays in the US. Adding Ryaltris(TM) is a significant step forward in expanding our US nasal spray leadership into branded medicines. Importantly, it will allow us to leverage our strong, existing specialty salesforce already calling on doctors with our specialty portfolio, and to potentially leverage our nasal spray manufacturing capabilities in Columbus, Ohio. We look forward to bringing this important new treatment option to millions of US patients."

"We are happy to partner with Hikma in the US as Ryaltris(TM) is a perfect strategic fit in their near-term plan to build a branded nasal spray portfolio. This partnership gives us an opportunity to tap into the largest pharmaceutical market in the world. This step is aligned with our vision to make Ryaltris(TM) the first global brand of Glenmark by launching it in several markets across the globe," said Glenn Saldanha, Chairman and Managing Director of Glenmark Pharmaceuticals.

Glenmark has studied Ryaltris(TM) in seven clinical trials involving more than 4,000 adult and adolescent patients (12 years of age and older). The FDA issued a Complete Response Letter (CRL) to Glenmark regarding the NDA for Ryaltris(TM) in June 2019, citing deficiencies pertaining to the proposed manufacturing facility. The CRL did not specify any deficiencies with the clinical data supporting the NDA for Ryaltris(TM).

About Seasonal Allergic Rhinitis

According to the most recent CDC data, almost 20 million adults in the United Sates are affected by seasonal allergic rhinitis every year. It is the primary diagnosis in over 11 million doctor's visits annually and is estimated to affect more than seven percent of adults aged 18 years and over in the United States.

- ENDS -

Enquiries

Glenmark Pharmaceuticals

 
Madhurima Gupta Jain                       +91 22 4018 9606 
 Senior Manager, Corporate Communications   corpcomm@glenmarkpharma.com 
 

Hikma Pharmaceuticals PLC

 
Susan Ringdal                                +44 (0)20 7399 2760/ +44 7776 
 EVP, Strategic Planning and Global Affairs   477050 
                                              uk-investors@hikma.uk.com 
Steve Weiss                                  +1 732 720 2830/ +1 732 788 
 David Belian                                 8279 
 US Communications and Public Affairs         +1 732 720 2814/+1 848 254 4875 
                                              u scommunications @hikma.com 
 

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Ltd. (GPL) is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries. Glenmark's key therapy focus areas globally are respiratory, dermatology and oncology. It is ranked among the top 80 Pharma & Biotech companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2019). For more information, visit www.glenmarkpharma.com

About Hikma

(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1/stable Moody's and BB+/positive S&P)

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRAEAFAKAAEEEAA

(END) Dow Jones Newswires

February 27, 2020 02:05 ET (07:05 GMT)

Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico


Da Giu 2019 a Giu 2020

Clicca qui per i Grafici di Hikma Pharmaceuticals

Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Intraday


Sabatp 6 Giugno 2020

Clicca qui per i Grafici di Hikma Pharmaceuticals
La tua Cronologia
BIT
BMPS
Monte Pasc..
BITI
FTSEMIB
FTSE Mib
BIT
UCG
Unicredit
NASDAQ
AAPL
Apple
FX
EURUSD
Euro vs Do..
Le azioni che visualizzerai appariranno in questo riquadro, così potrai facilmente tornare alle quotazioni di tuo interesse.

Registrati ora per creare la tua watchlist personalizzata in tempo reale streaming.

Per accedere al tempo reale push di Borsa è necessario registrarsi.

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

P: V:it D:20200606 12:07:22